Next Article in Journal
Characteristics of Indonesian Stingless Bee Propolis and Study of Metabolomic Properties Based on Region and Species
Previous Article in Journal
Phytochemical Investigations, Antioxidant and Insecticidal Properties of Essential Oil and Extracts from the Aerial Parts of Pelargonium graveolens from Morocco
Previous Article in Special Issue
Cytotoxic Activity of Lepidium virginicum L. Methanolic Extract on Human Colorectal Cancer Cells, Caco-2, through p53-Mediated Apoptosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 29
Issue 17
10.3390/molecules29174034
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Isolation of Anti-Prion Compounds from Curcuma phaeocaulis Valeton Extract

by
Jaehyeon Kim
†,
Hakmin Lee
†,
Hye Mi Kim
†,
Ji Hoon Kim
,
Sanghoon Byun
,
Sungeun Lee
,
Chul Young Kim
* and
Chongsuk Ryou
*
Department of Pharmacy, College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University ERICA, Ansan 15588, Gyeonggi-do, Republic of Korea
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Molecules 2024, 29(17), 4034; https://doi.org/10.3390/molecules29174034
Submission received: 24 June 2024 / Revised: 19 August 2024 / Accepted: 21 August 2024 / Published: 26 August 2024
(This article belongs to the Special Issue Natural Compounds for Disease and Health II)
Browse Figures
Versions Notes

Abstract

:
Prion diseases, known as a group of fatal neurodegenerative disorders caused by prions, remain incurable despite extensive research efforts. In a recent study, crude extract from Curcuma phaeocaulis Valeton (Cp) showed promising anti-prion efficacy in in vitro and in vivo models, prompting further investigation into their active compounds. We endeavored to identify the chemical constituents of the Cp extract and discover potential anti-prion agents. With the use of centrifugal partition chromatography (CPC), major constituents were isolated from the n-hexane (HX) fraction of the extract in a single step. Spectroscopic analysis confirmed the presence of curcumenone, curcumenol, and furanodienone. Subsequent efficacy testing in a cell culture model of prion disease identified curcumenol and furanodienone as active compounds. This study underscores the potential of natural products in the search for effective treatments against prion diseases.

1. Introduction

Prion diseases are a group of rare fatal neurodegenerative disorders caused by unconventional proteinaceous pathogens called prions [1]. They include Creutzfeldt–Jakob disease in humans and scrapie, bovine spongiform encephalopathy, and chronic wasting disease in animals [2]. Prions are composed of a misfolded isoform of cellular prion protein (PrPC), termed scrapie prion protein (PrPSc) [3]. Formed by the conformational conversion of PrPC, PrPSc begins to accumulate in the brain [4] where it directly and indirectly triggers neurotoxicity, leading to neuronal cell death, vacuolation, and spongiform degeneration [5].
Currently, prion diseases are incurable. Although no treatment in clinical use to ameliorate the course of prion disease is available [6], numerous agents from different classes have been investigated using in vitro and in vivo models [7]. Natural extracts and natural product-derived compounds also belong to these agents. Representative anti-prion agents obtained from natural extracts include baicalein from Scutellaria lateriflora L. [8], carnosic acid from Rosmarinus officinalis L. [9], curcumin from Curcuma longa L. [10], polydatin from Polygonum cuspidatum Siebold & Zucc. [11], cannabidiol from the Cannabis genus [12], hinokitiol from the Cupressus genus [13], epigallocatechin gallate from green tea [14], ginsenoside-RG3 from ginseng [15], resveratrol from a variety of fruits like grapes and berries [16], and trehalose from almost all organisms [17].
Curcuma phaeocaulis Valeton (Cp), a plant species in the Zingiberaceae family, is commonly found in East Asia and has been used as traditional herbal medicine to control conditions related to blood stasis, gastritis, and pain [18]. Phytochemical research has identified various bioactive constituents in Cp, particularly sesquiterpenoids, which exhibit a range of therapeutic properties for cancer [19], inflammation [20], and neurotoxic conditions [21]. Cp is also noted for its potential use in treating neurodegenerative diseases [22]. Specifically, several sesquiterpenoids in the Curcuma genus were reported to improve pathophysiological molecular and cellular events associated with Alzheimer’s disease [23,24,25,26] that shares similarities with prion disease in terms of neurodegeneration caused by protein misfolding and aggregation.
In our recent study, we reported the anti-prion efficacy of crude Cp extract [27]. The in vitro assay results demonstrated that Cp extract inhibited conversion and aggregation of misfolded PrP. Additionally, they suppressed prion infection in cultured neuroblastoma cells and the accumulation of PrPSc in the cultured neuroblastoma cells with chronic prion infection. Furthermore, the crude extract was effective in treating prion disease in a mouse model, showing prevention of disease onset, astrogliosis and spongiosis in the brain, as well as PrPSc accumulation in the brain and spleen in nearly 40% of prion-infected mice in the group.
It is important to identify the compounds of the Cp extract that result in beneficial efficacy. The aim of the current study is to determine the chemical constituents of the Cp extract and discover active anti-prion compounds in this extract. Separation and purification of bioactive molecules from natural products often require repeated chromatography, and sometimes the active ingredients may not elute due to absorption onto the solid phase. By enhancing separation efficiency and sample recovery, these challenges can be overcome through counter-current chromatography, such as centrifugal partition chromatography (CPC), which is a valid alternative [28,29]. CPC, a liquid–liquid chromatography technique utilizing two immiscible solvent phases, is an efficient tool for separating bioactive components from natural products based on their biological activity. It offers advantages such as a higher sample loading capacity, no sample loss due to irreversible absorption onto solid columns, flexible operation modes, and the ability to choose from a variety of solvent systems [30].
In this study, we isolated major constituents from the n-hexane (HX) fraction of the Cp extract using CPC in a single step. The isolated compounds were confirmed to be curcumenone (1), curcumenol (2), and furanodienone (3) using spectroscopic methods (MS and NMR). Finally, these compounds were applied to efficacy testing in a cell culture model of prion disease. This study successfully identified curcumenol (2) and furanodienone (3) as active compounds.

2. Results and Discussion

2.1. Activity-Guided Identification of Active Fractions in the Cp Extract for Anti-Prion Activity

To identify the active compounds in the crude Cp extract responsible for prion suppression described in a previous report [27], solvent fractionation was conducted using n-hexane (HX), ethyl acetate (EA), and water (DW) (Figure 1A). The major peaks found in the Cp extract were present in the HX fraction (Figure 1B). Subsequently, each fraction was used to incubate cultured neuroblastoma cells with chronic prion infection (ScN2a cells) according to the weight ratio of each fraction (Table S1). The level of PrPSc in ScN2a cells incubated with the HX fraction, but not the others, decreased to a comparable level observed for the crude extract (Figure 2). The anti-prion activity of the crude Cp extract shown in the current study was reminiscent of that reported in a previous study [27]. Although the anti-prion activity of the HX fraction and the crude Cp extract did not appear to be the same, the difference was not statistically significant. Taken together, the results indicate that the HX fraction retains the most activity to inhibit PrPSc accumulation in cultured cells, which was shown by the crude extract.

2.2. Isolation of Major Compounds from the Cp Extract by CPC

To reveal the active components of the crude extract, we aimed to separate the major peaks observed in the HPLC chromatogram of the extract. As mentioned earlier, since the major peaks of the extract were found in the HX fraction and this fraction exhibited anti-prion activity (Figure 1B and Figure 2), the HX fraction was used for further experiments to separate the major peaks.
Successful separation of target compounds by CPC necessitates the selection of an appropriate two-phase solvent system. To optimize CPC solvent conditions, the K-values of the major constituents in various solvent systems with different compositions and volume ratios of two immiscible solvents were evaluated (Table S2 and Figure S1). Based on this result, the solvent system HX:ethanol:water (10:7:3) exhibited the most effective separation for major constituents (Table 1). The K-values of curcumenone (1), curcumenol (2), and furanodienone (3) were 0.26, 0.58, and 2.14, respectively.
The preparative CPC operated in the ascending mode, with the lower phase as the mobile phase and the upper phase acting as the stationary phase. During the process, 4.7 g of HX fraction was fractionated in a single run of 330 min, the retention of the stationary phase in the coil was 69.5%, and the pressure was 82 bar. The preparative CPC chromatogram is shown in Figure 3. Analysis of the HPLC peak area showed that fractions II and III contained purified compounds (curcumenol (2) and curcumenone (1), respectively) of up to 90% (Figure 3), with 190.1 and 914.9 mg of curcumenone (1, 97.78%) and curcumenol (2, 94.80%), respectively, isolated and collected from 4.7 g of the HX fraction. CPC peak fraction I was further subjected to preparative HPLC using an isocratic mode, and furanodienone (3, 99.28%) was obtained with high purity.

2.3. Determination of Chemical Identity

The structural identification of CPC peak fractions (I–III) was carried out by ESI-MS, 1H-, and 13C-NMR (Figures S2–S8). In comparison to the reported data [31], the chemical structures of peak fractions I–III were elucidated as curcumenone (1), curcumenol (2), and furanodienone (3), respectively (Figure 4). Interestingly, none of these compounds shares chemical identity with curcumin, a compound widely found in the Curcuma genus and previously reported to inhibit PrP fibrilization and PrPSc accumulation in vitro [10].

2.4. Evaluation of the Anti-Prion Activity of the Major Compounds That Constitute the HX Fraction

To estimate the anti-prion activity of identified compounds included in the active HX fraction, the PrPSc level was measured in ScN2a cells incubated with non-cytotoxic concentrations of curcumenone (1), curcumenol (2), and furanodienone (3). Non-cytotoxic concentrations were determined by MTT assay. The results showed that ScN2a cells survived without cytotoxicity at and below 10 μM for curcumenone (1), 150 μM for curcumenol (2), 100 μM for furanodienone (3), 50 μg/mL for the crude Cp extract, and 22 μg/mL for the HX fraction (Figure S9). At the highest non-cytotoxic concentrations, the level of PrPSc was reduced by curcumenol (2) and furanodienone (3), but not by curcumenone (1), when compared to that found in the vehicle control (Figure 5). This reduction was comparable to the effect exhibited by the HX fraction, a positive control. The anti-prion activity of curcumenol (2) and furanodienone (3) occurred in a concentration-dependent fashion, although complete elimination of PrPSc was infeasible within the non-cytotoxic concentrations. These results suggest that the efficacy of the crude Cp extract in modulating prion propagation in cells and animals appears to be attributed to the anti-prion activity exerted by curcumenol (2) and furanodienone (3).
Although curcumenol (2) and furanodienone (3) each alone significantly reduced the PrPSc levels, the activity was insufficient to represent that of the crude Cp extract. This makes us speculate that the combination of two active compounds could be more efficient to suppress prion propagation than each compound alone. Thus, reconstitution of these two active compounds would imply the accomplishment of full anti-prion activity demonstrated by the crude extract.

3. Materials and Methods

3.1. Apparatus and Materials

Centrifugal partition chromatography (CPC) was carried out using an SCPC-100+1000 equipped with a Spot prep II LC system (Armen Instrument, Saint-Avé, France). HPLC analyses were performed using an Agilent 1260 Infinity HPLC system (Agilent Technologies, Waldbronn, Germany) managed by ChemStation software (B.04.03). Preparative HPLC for isolation was performed using a Gilson 321 pump (Gilson, Middleton, WI, USA) and Waters 2487 detector (Waters, Milford, MA, USA). For the structural identification of isolated compounds, a Waters Acquity UPLC system (Waters, Milford, MA, USA) equipped with an electrospray ionization source interfaced to an Advion expression CMS mass spectrometer (Advion, Ithaca, NY, USA) and an AVANCE III 400 spectrophotometer (Bruker, Ettlingen, Germany) were used. HPLC-grade acetonitrile and water were obtained from Daejung Chemical (Siheung, Republic of Korea), while analytical-grade formic acid was purchased from Sigma Aldrich (St. Louis, MO, USA). All additional organic solvents utilized for sample extraction and CPC separation were obtained from Daejung Chemical (Siheung, Republic of Korea).

3.2. Plant Material and Preparation of the Cp Extract

The plant materials of Cp were purchased from an oriental drug store (Kwang Myung Dang Co., Ulsan, Republic of Korea) and were authenticated by one of the corresponding authors (C.Y.K.). A voucher specimen (specimen no. HYUP-CP-001) has been deposited in the Pharmacognosy Laboratory of the College of Pharmacy, Hanyang University. The powdered Cp (482.0 g) was subjected to three extractions with 5 L of methanol using an ultrasonic apparatus at room temperature. The resulting extract was then concentrated in vacuo, yielding a methanol extract (33.3 g, 6.9%). This extract was suspended in water and successively fractionated with equal volumes of HX. The obtained HX fraction (12.0 g) was stored in a refrigerator for CPC separation.

3.3. Preparation of the Two-Phase Solvent System

The two-phase solvent system was determined based on the suitable partition coefficients (0.5 < K < 2.0) of the target compounds, tested across various solvent systems composed of pre-equilibrated n-hexane:ethanol:water. To achieve this, 10–15 mg of crude extract was dissolved in 1.8 mL of each phase of the immiscible two-phase solvent system in separate tubes. Each tube was vigorously shaken for several minutes and then allowed to reach equilibrium. Subsequently, equal volumes of the upper and lower phases were analyzed by HPLC at 254 nm. In this analysis, the upper organic phase served as the mobile phase, while the lower aqueous phase functioned as the stationary phase. The partition coefficient (K value) for each compound was determined by calculating the ratio of the peak area in the upper phase to that in the lower phase.

3.4. CPC and Preparative HPLC Separation of the HX Fraction

Based on the appropriate K values, CPC separation was carried out using a two-phase solvent system consisting of n-hexane–ethanol–water (10:7:3, v/v/v). The biphasic solvent system was prepared by thorough mixing and complete equilibration of the upper and lower phase solvents. The CPC rotor was initially filled with the lower layer as the stationary phase. Subsequently, the rotation speed of the rotor was increased to 1100 rpm, and the upper layer, serving as the mobile phase, was introduced into the rotor in ascending mode with a flow rate of 10 mL/min. Once the CPC rotor attained equilibrium in the immiscible biphasic state (with 730 mL of the stationary phase out of a total rotor volume of 1000 mL, at a pressure of 82 bar), 4.7 g of HX fraction dissolved in a 14 mL mixture of the upper and lower phases was introduced into the CPC system. The effluent was monitored at wavelengths of 254 and 280 nm. Every peak fraction was collected at 25 mL per tube and separated according to the elution profile to yield three CPC peak fractions I–III. The fractions were dried and analyzed by HPLC. As a result, compounds 1 and 2 were obtained with high purity; compound 1 (190.1 mg) from CPC peak fraction III; compound 2 (914.9 mg) from CPC peak fraction II. For the further purification of the CPC peak fraction I, preparative HPLC was conducted with a Cosmosil C18 column (5 µm, 20.0 × 150 mm) to purify compound 3 (15.0 mg).

3.5. HPLC Analysis

The extract and the CPC peak fraction were analyzed by HPLC equipped with a Hector C18 column (5 µm, 4.6 × 250 mm). The mobile phase was composed of 0.1% formic acid in both water (A) and acetonitrile (B), with the gradient elution conditions as follows: 0–5 min (25–50% B), 5–10 min (50–70% B), 10–22 min (70% B), 22–25 min (70–100% B), and 25–30 min (100% B). The injection volume was 10 µL, and the flow rate was kept at 1 mL/min. The diode array detector recorded the UV spectrum from 210–400 nm, and the chromatogram was monitored at 254 nm.

3.6. Structural Elucidation

The structural elucidation of the isolated compounds was carried out by ESI-MS and NMR analysis. NMR spectra were obtained in chloroform-d and processed using MestReNova (Mnova) 9.0 software (Mestrelab Research Inc., Santiago de Compostela, Spain). Additionally, the conditions for the ESI-MS spectra were as follows: positive ion mode; mass range of m/z 100–1200; capillary temperature set to 200 ℃; capillary voltage at 150 V; source voltage offset of 30; source voltage span of 10; source gas temperature at 150 ℃; and ESI voltage of 3500 V. The 1H-, 13C-NMR, and ESI-MS spectra of isolated compounds 1–3 are shown in Supplementary Materials.

3.7. Measurement of PrPSc Levels and Cytotoxicity in ScN2a Cells

Curcumenone (1), curcumenol (2), and furanodienone (3) (purity ≥ 98%) were purchased from Chemfaces (Wuhan, China). The compounds were dissolved in dimethyl sulfoxide and used for the assays. The cytotoxicity of the compounds was determined by MTT assay as previously described [32]. Briefly, ScN2a cells were cultured with the compounds for 4 days, and the level of formazan formation from MTT agents (Sigma, St. Louis, MO, USA) by cellular enzymes was measured with the Infinite M200Pro Multimode Reader (Tecan, Männedorf, Switzerland) at 570 nm. The level of PrPSc in ScN2a cells was analyzed as previously described [13]. Briefly, ScN2a cells were cultured with the compounds for 4 days at non-cytotoxic concentrations (>90% of cell viability), and proteinase K (PK) (Roche, Basel, Switzerland)-resistant PrPSc in cell lysates was analyzed by Western blotting using mouse monoclonal anti-PrP antibody 6D11 (Biolegend, San Diego, CA, USA). Separately, β-actin, as a loading control marker, was detected using mouse monoclonal anti-β-antibody AC-15 (Santa Cruz Biotechnology, Dallas, TX, USA). Densitometry of Western blots was performed using Gene Tools 4.1 software (Syngene, San Diego, CA, USA). Student’s t-test was used for statistical analysis.

4. Conclusions

This study presents the successful establishment of a bioactivity-guided separation method using CPC to isolate and purify active compounds from effective Cp extract against prion diseases. Following the activity screening of solvent fractions from the extract, the HX fraction was revealed to retain anti-prion activity exhibited by the crude extract. The application of CPC makes it possible to achieve the effective separation and high-yield purification of major compounds from the HX fraction in a single step. Structural elucidation by spectroscopic analysis identified major compounds as curcumenone (1), curcumenol (2), and furanodienone (3). Estimation of the anti-prion activity of these compounds confirmed curcumenol (2) and furanodienone (3) are the active ones, showing significant efficacy to reduce PrPSc accumulation in a cell culture model of prion disease. Further research in animal models is needed to explore whether these compounds are able to modify the course of disease and ameliorate neuropathological and molecular biomarkers associated with prion disease. Enhancing the potential for therapeutic applications, this finding contributes to ongoing efforts to develop treatments for prion diseases. Additionally, the current study emphasizes the importance of natural product-based research for drug discovery to combat prion disease.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/molecules29174034/s1, Table S1: Fraction weights and percent ratio of solvent-fractionated Cp extract; Table S2: The partition coefficients (K) of target compounds of the HX fraction in different solvent systems; Figure S1: HPLC chromatogram at 254 nm of the HX fraction from Cp extract; Figure S2: 1H-NMR (400 MHz) spectrum of curcumenone (1) in chloroform-d; Figure S3: 13C-NMR (100 MHz) spectrum of curcumenone (1) in chloroform-d; Figure S4: 1H-NMR (400 MHz) spectrum of curcumenol (2) in chloroform-d; Figure S5: 13C-NMR (100 MHz) spectrum of curcumenol (2) in chloroform-d; Figure S6: 1H-NMR (400 MHz) spectrum of furanodienone (3) in chloroform-d; Figure S7: 13C-NMR (100 MHz) spectrum of furanodienone (3) in chloroform-d; Figure S8: ESI-MS spectrum of isolated compounds; Figure S9: Cytotoxicity of identified compounds from the HX fraction.

Author Contributions

Conceptualization, C.Y.K. and C.R.; methodology, J.K., H.L., H.M.K., C.Y.K. and C.R.; validation, H.M.K., S.B. and S.L.; formal analysis, J.K., H.L., H.M.K., J.H.K., C.Y.K. and C.R.; investigation, J.K., H.L., H.M.K., J.H.K., C.Y.K. and C.R.; resources, C.Y.K. and C.R.; data curation, J.K., H.L., H.M.K., J.H.K., C.Y.K. and C.R.; writing—original draft preparation, J.K., H.M.K., S.L., C.Y.K. and C.R.; writing—review and editing, C.Y.K. and C.R.; visualization, J.K., H.L. and H.M.K.; supervision, C.Y.K. and C.R.; project administration, C.Y.K. and C.R.; funding acquisition, C.Y.K. and C.R. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2020R1A6A1A03042854). The APC was funded in part by ERICA Outstands Program, Hanyang University ERICA.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All data generated or analyzed during this study are included in this published article and its Supplementary Materials.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Stahl, N.; Prusiner, S.B. Prions and prion proteins. FASEB J. 1991, 5, 2799–2807. [Google Scholar] [CrossRef] [PubMed]
  2. Requena, J.R.; Wille, H. The structure of the infectious prion protein and its propagation. Prog. Mol. Biol. Transl. Sci. 2017, 150, 341–359. [Google Scholar]
  3. Ryou, C.-S. Prions and prion diseases: Fundamentals and mechanistic details. J. Microbiol. Biotechn 2007, 17, 1059–1070. [Google Scholar]
  4. Ghetti, B.; Piccardo, P.; Frangione, B.; Bugiani, O.; Giaccone, G.; Young, K.; Prelli, F.; Farlow, M.R.; Dlouhy, S.R.; Tagliavini, F. Prion protein amyloidosis. Brain Pathol. 1996, 6, 127–145. [Google Scholar] [CrossRef] [PubMed]
  5. Ketzschmar, H.; Giese, A.; Brown, D.; Herms, J.; Keller, B.; Schmidt, B.; Groschup, M. Cell death in prion disease. J. Neural Transm. Suppl. 1997, 50, 191–210. [Google Scholar]
  6. Forloni, G.; Artuso, V.; Roiter, I.; Morbin, M.; Tagliavini, F. Therapy in prion diseases. Curr. Top. Med. Chem. 2013, 13, 2465–2476. [Google Scholar] [CrossRef] [PubMed]
  7. Shim, K.H.; Sharma, N.; An, S.S.A. Prion therapeutics: Lessons from the past. Prion 2022, 16, 265–294. [Google Scholar] [CrossRef]
  8. Eiden, M.; Leidel, F.; Strohmeier, B.; Fast, C.; Groschup, M.H. A medicinal herb Scutellaria lateriflora inhibits PrP replication in vitro and delays the onset of prion disease in mice. Front. Psychiatry 2012, 3, 9. [Google Scholar] [CrossRef]
  9. Karagianni, K.; Pettas, S.; Kanata, E.; Lioulia, E.; Thune, K.; Schmitz, M.; Tsamesidis, I.; Lymperaki, E.; Xanthopoulos, K.; Sklaviadis, T.; et al. Carnosic acid and carnosol display antioxidant and anti-prion properties in in vitro and cell-free models of prion diseases. Antioxidants 2022, 11, 726. [Google Scholar] [CrossRef]
  10. Caughey, B.; Raymond, L.D.; Raymond, G.J.; Maxson, L.; Silveira, J.; Baron, G.S. Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J. Virol. 2003, 77, 5499–5502. [Google Scholar] [CrossRef]
  11. Sirohi, P.R.; Kumari, A.; Admane, N.; Somvanshi, P.; Grover, A. The polyphenolic phytoalexin polydatin inhibits amyloid aggregation of recombinant human prion protein. RSC Adv. 2021, 11, 25901–25911. [Google Scholar] [CrossRef]
  12. Dirikoc, S.; Priola, S.A.; Marella, M.; Zsurger, N.; Chabry, J. Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity. J. Neurosci. 2007, 27, 9537–9544. [Google Scholar] [CrossRef] [PubMed]
  13. Moon, J.H.; Lee, J.H.; Lee, Y.J.; Park, S.Y. Hinokitiol protects primary neuron cells against prion peptide-induced toxicity via autophagy flux regulated by hypoxia inducing factor-1. Oncotarget 2016, 7, 29944–29957. [Google Scholar] [CrossRef] [PubMed]
  14. Lee, J.H.; Moon, J.H.; Kim, S.W.; Jeong, J.K.; Nazim, U.M.D.; Lee, Y.J.; Seol, J.W.; Park, S.Y. EGCG-mediated autophagy flux has a neuroprotection effect via a class III histone deacetylase in primary neuron cells. Oncotarget 2015, 6, 9701–9717. [Google Scholar] [CrossRef] [PubMed]
  15. Moon, J.H.; Lee, J.H.; Lee, Y.J.; Park, S.Y. Autophagy flux induced by ginsenoside-Rg3 attenuates human prion protein-mediated neurotoxicity and mitochondrial dysfunction. Oncotarget 2016, 7, 85697–85708. [Google Scholar] [CrossRef]
  16. Wang, J.; Zhang, B.Y.; Zhang, J.; Xiao, K.; Chen, L.N.; Wang, H.; Sun, J.; Shi, Q.; Dong, X.P. Treatment of SMB-S15 cells with resveratrol efficiently removes the PrP(Sc) accumulation in vitro and prion infectivity in vivo. Mol. Neurobiol. 2016, 53, 5367–5376. [Google Scholar] [CrossRef]
  17. Aguib, Y.; Heiseke, A.; Gilch, S.; Riemer, C.; Baier, M.; Schatzl, H.M.; Ertmer, A. Autophagy induction by trehalose counteracts cellular prion infection. Autophagy 2009, 5, 361–369. [Google Scholar] [CrossRef]
  18. Zhou, Y.; Xie, M.; Song, Y.; Wang, W.; Zhao, H.; Tian, Y.; Wang, Y.; Bai, S.; Zhao, Y.; Chen, X. Two traditional Chinese medicines Curcumae radix and Curcumae rhizoma: An ethnopharmacology, phytochemistry, and pharmacology review. Evid.-Based Complement. Altern. Med. 2016, 2016, 4973128. [Google Scholar] [CrossRef]
  19. Chen, X.; Pei, L.; Zhong, Z.; Guo, J.; Zhang, Q.; Wang, Y. Anti-tumor potential of ethanol extract of Curcuma phaeocaulis Valeton against breast cancer cells. Phytomedicine 2011, 18, 1238–1243. [Google Scholar] [CrossRef]
  20. Hou, Y.; Lu, C.-L.; Zeng, Q.-H.; Jiang, J.-G. Anti-inflammatory, antioxidant and antitumor activities of ingredients of curcuma phaeocaulis val. EXCLI J. 2015, 14, 706. [Google Scholar]
  21. Dohare, P.; Garg, P.; Sharma, U.; Jagannathan, N.; Ray, M. Neuroprotective efficacy and therapeutic window of curcuma oil: In rat embolic stroke model. BMC Complement. Altern. Med. 2008, 8, 55. [Google Scholar] [CrossRef] [PubMed]
  22. Yu, C.; Sun, X.; Niu, Y. An investigation of the developmental neurotoxic potential of curcumol in PC12 cells. Toxicol. Mech. Methods 2016, 26, 635–643. [Google Scholar] [CrossRef] [PubMed]
  23. Wu, P.Q.; Li, B.; Yu, Y.F.; Su, P.J.; Liu, X.; Zhang, Z.P.; Zhi, D.J.; Qi, F.M.; Fei, D.Q.; Zhang, Z.X. Isolation, characterization, and possible anti-alzheimer’s disease activities of bisabolane-type sesquiterpenoid derivatives and phenolics from the rhizomes of Curcuma longa. Chem. Biodivers. 2020, 17, e2000067. [Google Scholar] [CrossRef]
  24. Wang, Z.Y.; Liu, J.G.; Li, H.; Yang, H.M. Pharmacological effects of active components of Chinese herbal medicine in the treatment of alzheimer’s disease: A review. Am. J. Chin. Med. 2016, 44, 1525–1541. [Google Scholar] [CrossRef] [PubMed]
  25. Borah, S.; Sarkar, P.; Sharma, H.K. Zederone improves the fecal microbial profile in dementia induced rat model: A first report. CNS Neurol. Disord. Drug Targets 2022, 21, 335–342. [Google Scholar] [CrossRef]
  26. Dubey, T.; Sonawane, S.K.; Mannava, M.C.; Nangia, A.K.; Chandrashekar, M.; Chinnathambi, S. The inhibitory effect of curcumin-artemisinin co-amorphous on tau aggregation and tau phosphorylation. Colloids Surf. B Biointerfaces 2023, 221, 112970. [Google Scholar] [CrossRef] [PubMed]
  27. Lee, S.; Lee, H.; Kim, J.; Kim, J.H.; Gao, E.M.; Lee, Y.; Yoo, M.; Trinh, T.H.; Kim, J.; Kim, C.Y. The effect of Curcuma phaeocaulis Valeton (Zingiberaceae) extract on prion propagation in cell-based and animal models. Int. J. Mol. Sci. 2022, 24, 182. [Google Scholar] [CrossRef]
  28. Marston, A.; Borel, C.; Hostettmann, K. Separation of natural products by centrifugal partition chromatography. J. Chromatogr. A 1988, 450, 91–99. [Google Scholar] [CrossRef]
  29. Foucault, A.; Chevolot, L. Counter-current chromatography: Instrumentation, solvent selection and some recent applications to natural product purification. J. Chromatogr. A 1998, 808, 3–22. [Google Scholar] [CrossRef]
  30. Hostettmann, K.; Marston, A. Liquid-liquid partition chromatography in natural product isolation. Anal. Chim. Acta 1990, 236, 63–76. [Google Scholar] [CrossRef]
  31. Hamdi, O.A.A.; Anouar, E.H.; Shilpi, J.A.; Trabolsy, Z.B.K.A.; Zain, S.B.M.; Zakaria, N.S.S.; Zulkefeli, M.; Weber, J.-F.F.; Malek, S.N.A.; Rahman, S.N.S.A. A quantum chemical and statistical study of cytotoxic activity of compounds isolated from Curcuma zedoaria. Int. J. Mol. Sci. 2015, 16, 9450–9468. [Google Scholar] [CrossRef] [PubMed]
  32. Waqas, M.; Lee, H.-M.; Kim, J.; Telling, G.; Kim, J.-K.; Kim, D.-H.; Ryou, C. Effect of poly-L-arginine in inhibiting scrapie prion protein of cultured cells. Mol. Cell Biochem. 2017, 428, 57–66. [Google Scholar] [CrossRef] [PubMed]
Molecules 29 04034 g001
Figure 1. Solvent fractionation of crude Cp extract. (a) Fractionation scheme. (b) HPLC chromatograms of crude extract and sub-fractions. HX, n-hexane; EA, ethyl acetate; ED, unmixed portion of EA and DW fractions; DW, distilled water.
Figure 1. Solvent fractionation of crude Cp extract. (a) Fractionation scheme. (b) HPLC chromatograms of crude extract and sub-fractions. HX, n-hexane; EA, ethyl acetate; ED, unmixed portion of EA and DW fractions; DW, distilled water.
Molecules 29 04034 g001
Molecules 29 04034 g002
Figure 2. The level of PK-resistant PrPSc in the cells incubated with solvent-extracted Cp fractions. (a) A representative Western blot of PK-resistant (res) PrPSc. The crude Cp extract was evaluated for anti-prion activity at a concentration of 50 μg/mL, and each solvent-extracted fraction was used to incubate ScN2a cells at the concentration of assigned weight ratios as in Table S1. (b) Densitometry analysis of PK-resistant PrPSc. n = 4. * p-value < 0.05; ** p-value < 0.01.
Figure 2. The level of PK-resistant PrPSc in the cells incubated with solvent-extracted Cp fractions. (a) A representative Western blot of PK-resistant (res) PrPSc. The crude Cp extract was evaluated for anti-prion activity at a concentration of 50 μg/mL, and each solvent-extracted fraction was used to incubate ScN2a cells at the concentration of assigned weight ratios as in Table S1. (b) Densitometry analysis of PK-resistant PrPSc. n = 4. * p-value < 0.05; ** p-value < 0.01.
Molecules 29 04034 g002
Molecules 29 04034 g003
Figure 3. CPC chromatogram of the HX fraction (a) and HPLC analysis of CPC peak fractions I–III (b). CPC conditions: two-phase solvent system, n-hexane:ethanol:water (10:7:3, v/v/v); ascending mode; flow rate of 10 mL/min; rotation speed of 1200 rpm; monitored at 254 (black line) and 280 (gray line) nm. HPLC conditions are the same as those described above.
Figure 3. CPC chromatogram of the HX fraction (a) and HPLC analysis of CPC peak fractions I–III (b). CPC conditions: two-phase solvent system, n-hexane:ethanol:water (10:7:3, v/v/v); ascending mode; flow rate of 10 mL/min; rotation speed of 1200 rpm; monitored at 254 (black line) and 280 (gray line) nm. HPLC conditions are the same as those described above.
Molecules 29 04034 g003
Molecules 29 04034 g004
Figure 4. Chemical structures of the isolated compounds from Cp extract.
Figure 4. Chemical structures of the isolated compounds from Cp extract.
Molecules 29 04034 g004
Molecules 29 04034 g005
Figure 5. The level of PK-resistant PrPSc in the cells incubated with major compounds that constitute the HX fraction. (a) Representative Western blots of PK-resistant (res) PrPSc. Cells were incubated with non-cytotoxic concentrations or below for each compound, HX fraction, and crude extract. (b) Densitometry analysis of PK-resistant PrPSc. n = 4. ** p-value < 0.01; *** p-value < 0.001.
Figure 5. The level of PK-resistant PrPSc in the cells incubated with major compounds that constitute the HX fraction. (a) Representative Western blots of PK-resistant (res) PrPSc. Cells were incubated with non-cytotoxic concentrations or below for each compound, HX fraction, and crude extract. (b) Densitometry analysis of PK-resistant PrPSc. n = 4. ** p-value < 0.01; *** p-value < 0.001.
Molecules 29 04034 g005
Table 1. The K-values of three main compounds of the HX fraction of Cp extract.
Table 1. The K-values of three main compounds of the HX fraction of Cp extract.
n-HX:ethanol:water (v/v/v)K-Values
Curcumenone (1)Curcumenol (2)Furanodienone (3)
10:9:10.270.440.81
10:8:20.200.411.18
10:7:30.260.582.14
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kim, J.; Lee, H.; Kim, H.M.; Kim, J.H.; Byun, S.; Lee, S.; Kim, C.Y.; Ryou, C. Isolation of Anti-Prion Compounds from Curcuma phaeocaulis Valeton Extract. Molecules 2024, 29, 4034. https://doi.org/10.3390/molecules29174034

AMA Style

Kim J, Lee H, Kim HM, Kim JH, Byun S, Lee S, Kim CY, Ryou C. Isolation of Anti-Prion Compounds from Curcuma phaeocaulis Valeton Extract. Molecules. 2024; 29(17):4034. https://doi.org/10.3390/molecules29174034

Chicago/Turabian Style

Kim, Jaehyeon, Hakmin Lee, Hye Mi Kim, Ji Hoon Kim, Sanghoon Byun, Sungeun Lee, Chul Young Kim, and Chongsuk Ryou. 2024. "Isolation of Anti-Prion Compounds from Curcuma phaeocaulis Valeton Extract" Molecules 29, no. 17: 4034. https://doi.org/10.3390/molecules29174034

APA Style

Kim, J., Lee, H., Kim, H. M., Kim, J. H., Byun, S., Lee, S., Kim, C. Y., & Ryou, C. (2024). Isolation of Anti-Prion Compounds from Curcuma phaeocaulis Valeton Extract. Molecules, 29(17), 4034. https://doi.org/10.3390/molecules29174034

Article Metrics

Back to TopTop